Paper Details

  1. Home
  2. Paper Details

LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial.

Author: GiuglianoRobert, Gouni-BertholdIoanna, ImKyungAh, KeechAnthony, KnuselBeat, O'DonoghueMichelle L, PedersenTerje R, SabatineMarc S, SeverPeter, WangHuei

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Evolocumab showed consistent efficacy and safety across a broad range of ages and in both men and women in 27,564 patients with atherosclerotic cardiovascular disease.
Paper Details　
Original Abstract of the Article :
AIMS: Some trials have reported diminished efficacy for statins in the elderly, and in women compared with men. We examined the efficacy and safety of evolocumab by patient age and sex in the FOURIER trial, the first major cardiovascular outcome trial of a PCSK9 inhibitor. METHODS AND RESULTS: FOUR...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/2047487320902750

データ提供：米国国立医学図書館（NLM）

Evolocumab: A Promising LDL-Lowering Therapy Across Ages and Sexes

This study explores the efficacy and safety of evolocumab, a PCSK9 inhibitor, in lowering LDL-cholesterol levels and reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. The study analyzes data from the FOURIER trial, a large randomized, double-blind trial involving 27,564 patients receiving statin therapy. The study found that evolocumab was effective in lowering LDL-cholesterol levels and reducing cardiovascular events, regardless of patient age or sex. The study's findings suggest that evolocumab is a safe and effective treatment option for a broad range of patients with cardiovascular disease, offering a promising strategy for lowering LDL-cholesterol and reducing cardiovascular risk.

Evolocumab: An Oasis in the Desert of Cardiovascular Risk

This study offers a beacon of hope for those seeking to manage cardiovascular risk, showcasing the efficacy and safety of evolocumab across a wide range of individuals. The study's findings suggest that evolocumab can be a valuable tool for lowering LDL-cholesterol and reducing cardiovascular events, regardless of age or sex. This research is like discovering a hidden oasis in the vast desert of cardiovascular disease, offering a source of relief and a path towards improved health outcomes. It's a reminder that even in the face of seemingly insurmountable challenges, there is always hope for progress and innovation.

A Compass for Cardiovascular Health

This research provides a valuable compass for clinicians and patients seeking to manage cardiovascular risk. The study's findings suggest that evolocumab can be a safe and effective treatment option, offering a promising strategy for lowering LDL-cholesterol and reducing cardiovascular events across a broad range of individuals. This research is like a guidepost in the desert of cardiovascular disease, helping us to navigate the complexities of this condition and to discover new paths toward improved patient care.

Dr. Camel's Conclusion

This study demonstrates the efficacy and safety of evolocumab in lowering LDL-cholesterol levels and reducing cardiovascular events in patients with atherosclerotic cardiovascular disease, regardless of patient age or sex, offering a promising treatment option for a broad range of individuals.

Date :
  1. Date Completed 2021-12-13
  2. Date Revised 2022-04-29
Further Info :

Pubmed ID

34298555

DOI: Digital Object Identifier

10.1177/2047487320902750

Related Literature

Article Analysis
・Effects of evolocumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.